camostat has been researched along with Acantholysis Bullosa in 2 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaneko, F | 1 |
| Tsukinaga, I | 1 |
| Ando, M | 1 |
| Ohkawara, A | 1 |
| Oguchi, H | 1 |
| Oikawa, K | 1 |
| Nagai, M | 1 |
| Ikeda, S | 1 |
| Manabe, M | 1 |
| Muramatsu, T | 1 |
| Takamori, K | 1 |
| Ogawa, H | 1 |
2 other studies available for camostat and Acantholysis Bullosa
| Article | Year |
|---|---|
Studies on two siblings with recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) and the plasminogen activator and its inhibitor in the lesion.
Topics: Adolescent; Child; Epidermolysis Bullosa; Esters; Female; Gabexate; Genes, Recessive; Guanidines; HL | 1989 |
Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa. In vitro effect and clinical trial with camostat mesylate.
Topics: Administration, Topical; Adolescent; Adult; Blister; Child; Epidermolysis Bullosa; Esters; Female; G | 1988 |